Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$103.4M
Filings
355
Firms Hired
6
Active Period
2000–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
HR 1414 - Camerons Law, to restore orphan drug research tax credit HR 1990 - American Innovation and R&D Competitiveness Act of 2025 S 1605 - International Competition for American Jobs Act S 3841 - Last Sale Valuation Act of 2026 Most Favored Nations and pharmaceutical R&D innovation Tax incentives for manufacturing workforce development Tax proposals building on One Big Beautiful Bill Act law and implementation (R&D expensing, BEAT, FDII, Corporate Alternative Minimum Tax)
Client expense: $810,000 · Firm income: —
Matched citations: HR 1414
American Innovation and R&D Competitiveness Act of 2025
2026 · third_quarter · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 1414 - Camerons Law, to restore orphan drug research tax credit HR 1990 - American Innovation and R&D Competitiveness Act of 2025 S 1605 - International Competition for American Jobs Act S 3841 - Last Sale Valuation Act of 2026 Most Favored Nations and pharmaceutical R&D innovation Tax incentives for manufacturing workforce development Tax proposals building on One Big Beautiful Bill Act law and implementation (R&D expensing, BEAT, FDII, Corporate Alternative Minimum Tax)
Client expense: $810,000 · Firm income: —
Matched citations: HR 1990
Clinical Trial Modernization Act
2026 · third_quarter · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3521/ S 4440 Clinical Trial Modernization Act HR 946/S 1862 Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act Discuss Vaccine concerns Cell Therapy Broad discussion on drug pricing CMMI GENEROUS Demo FDA modernization policy 340B policy Demo for CMMI regarding copay caps Policies related to international reference pricing for pharmaceuticals Issues related to pharmacy benefit manager (PBM) reform Issues related to mitigation of 340B Issues and policies related to 340B Rebate Model Pilot Program for IRA compliance Issues related to most-favored nations drug pricing proposals Issues related to implementation and/or expansion of the Inflation Reduction Act (IRA) Issues related to the price and manufacture of inhaled medicines Issues related to next generation propellant and PFAS Issues related to vaccine access and vaccine R&D, including ACIP recommendations Issues related to the development of novel therapies including cell therapy and antibody drug conjugates (ADCs) Issues related to the recruitment of patients for clinical trials clinical trial modernization act
Client expense: $810,000 · Firm income: —
Matched citations: HR 3521
Prescription Information Modernization Act of 2025
2026 · third_quarter · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 4132/S 2027, Prescription Information Modernization Act; E-labeling (allowing health care providers to receive prescribing information for drugs electronically rather than in paper form from manufacturers) Issues related to increasing production of US manufacturing
Client expense: $810,000 · Firm income: —
Matched citations: HR 4132
Genomic Answers for Children’s Health Act of 2026
2026 · third_quarter · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 7118 Genomic Answers for Children's Health Act HR 9599 The SECURE 340B Act Policies related to the use of international reference pricing in Medicare/Medicaid 340B rebate model Issues related to Part B and Part D drug access Medicare drug price negotiation Medicare patient access to cancer screening Medicare patient access to rare disease therapies Efforts to improve coding, coverage, and access for rare disease therapies Issues related to e-labeling and allowing FDA to finalize a rule to allow digital versions of prescriptions Issues related to a Most Favored Nations policy in Medicare and Medicaid Most Favored Nation drug pricing proposals Issues related to the digital communication of prescribing information for drugs
Client expense: $810,000 · Firm income: —
Matched citations: HR 7118
HR 3521/ S 4440 Clinical Trial Modernization Act HR 946/S 1862 Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act Discuss Vaccine concerns Cell Therapy Broad discussion on drug pricing CMMI GENEROUS Demo FDA modernization policy 340B policy Demo for CMMI regarding copay caps Policies related to international reference pricing for pharmaceuticals Issues related to pharmacy benefit manager (PBM) reform Issues related to mitigation of 340B Issues and policies related to 340B Rebate Model Pilot Program for IRA compliance Issues related to most-favored nations drug pricing proposals Issues related to implementation and/or expansion of the Inflation Reduction Act (IRA) Issues related to the price and manufacture of inhaled medicines Issues related to next generation propellant and PFAS Issues related to vaccine access and vaccine R&D, including ACIP recommendations Issues related to the development of novel therapies including cell therapy and antibody drug conjugates (ADCs) Issues related to the recruitment of patients for clinical trials clinical trial modernization act
Client expense: $810,000 · Firm income: —
Matched citations: HR 946
HR 7118 Genomic Answers for Children's Health Act HR 9599 The SECURE 340B Act Policies related to the use of international reference pricing in Medicare/Medicaid 340B rebate model Issues related to Part B and Part D drug access Medicare drug price negotiation Medicare patient access to cancer screening Medicare patient access to rare disease therapies Efforts to improve coding, coverage, and access for rare disease therapies Issues related to e-labeling and allowing FDA to finalize a rule to allow digital versions of prescriptions Issues related to a Most Favored Nations policy in Medicare and Medicaid Most Favored Nation drug pricing proposals Issues related to the digital communication of prescribing information for drugs
Client expense: $810,000 · Firm income: —
Matched citations: HR 9599
International Competition for American Jobs Act
2026 · third_quarter · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 1414 - Camerons Law, to restore orphan drug research tax credit HR 1990 - American Innovation and R&D Competitiveness Act of 2025 S 1605 - International Competition for American Jobs Act S 3841 - Last Sale Valuation Act of 2026 Most Favored Nations and pharmaceutical R&D innovation Tax incentives for manufacturing workforce development Tax proposals building on One Big Beautiful Bill Act law and implementation (R&D expensing, BEAT, FDII, Corporate Alternative Minimum Tax)
Client expense: $810,000 · Firm income: —
Matched citations: S 1605
HR 3521/ S 4440 Clinical Trial Modernization Act HR 946/S 1862 Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act Discuss Vaccine concerns Cell Therapy Broad discussion on drug pricing CMMI GENEROUS Demo FDA modernization policy 340B policy Demo for CMMI regarding copay caps Policies related to international reference pricing for pharmaceuticals Issues related to pharmacy benefit manager (PBM) reform Issues related to mitigation of 340B Issues and policies related to 340B Rebate Model Pilot Program for IRA compliance Issues related to most-favored nations drug pricing proposals Issues related to implementation and/or expansion of the Inflation Reduction Act (IRA) Issues related to the price and manufacture of inhaled medicines Issues related to next generation propellant and PFAS Issues related to vaccine access and vaccine R&D, including ACIP recommendations Issues related to the development of novel therapies including cell therapy and antibody drug conjugates (ADCs) Issues related to the recruitment of patients for clinical trials clinical trial modernization act
Client expense: $810,000 · Firm income: —
Matched citations: S 1862
Prescription Information Modernization Act of 2025
2026 · third_quarter · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 4132/S 2027, Prescription Information Modernization Act; E-labeling (allowing health care providers to receive prescribing information for drugs electronically rather than in paper form from manufacturers) Issues related to increasing production of US manufacturing
Client expense: $810,000 · Firm income: —
Matched citations: S 2027
Last Sale Valuation Act of 2026
2026 · third_quarter · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 1414 - Camerons Law, to restore orphan drug research tax credit HR 1990 - American Innovation and R&D Competitiveness Act of 2025 S 1605 - International Competition for American Jobs Act S 3841 - Last Sale Valuation Act of 2026 Most Favored Nations and pharmaceutical R&D innovation Tax incentives for manufacturing workforce development Tax proposals building on One Big Beautiful Bill Act law and implementation (R&D expensing, BEAT, FDII, Corporate Alternative Minimum Tax)
Client expense: $810,000 · Firm income: —
Matched citations: S 3841
Clinical Trial Modernization Act
2026 · third_quarter · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3521/ S 4440 Clinical Trial Modernization Act HR 946/S 1862 Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act Discuss Vaccine concerns Cell Therapy Broad discussion on drug pricing CMMI GENEROUS Demo FDA modernization policy 340B policy Demo for CMMI regarding copay caps Policies related to international reference pricing for pharmaceuticals Issues related to pharmacy benefit manager (PBM) reform Issues related to mitigation of 340B Issues and policies related to 340B Rebate Model Pilot Program for IRA compliance Issues related to most-favored nations drug pricing proposals Issues related to implementation and/or expansion of the Inflation Reduction Act (IRA) Issues related to the price and manufacture of inhaled medicines Issues related to next generation propellant and PFAS Issues related to vaccine access and vaccine R&D, including ACIP recommendations Issues related to the development of novel therapies including cell therapy and antibody drug conjugates (ADCs) Issues related to the recruitment of patients for clinical trials clinical trial modernization act
Client expense: $810,000 · Firm income: —
Matched citations: S 4440
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: TODD STRATEGY GROUP
CMMI GENEROUS Demo. Most Favored Nation (MFN). Implementation of the Inflation Reduction Act (IRA) including orphan drug exclusion. Issues related to the Medicare title in Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA). Issues relating to Medicare Parts B and D. Medicare Drug Price Negotiation Program. PBM Reform. 340B Rebate Model Pilot Program. H.R.9599: The SECURE 340B Act. Implementation of Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
Client expense: — · Firm income: $80,000
Matched citations: H.R.1
Clinical Trial Modernization Act
2026 · third_quarter · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.3521
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.5509
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
CMMI GENEROUS Demo. Most Favored Nation (MFN). Implementation of the Inflation Reduction Act (IRA) including orphan drug exclusion. Issues related to the Medicare title in Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA). Issues relating to Medicare Parts B and D. Medicare Drug Price Negotiation Program. PBM Reform. 340B Rebate Model Pilot Program. H.R.9599: The SECURE 340B Act. Implementation of Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
Client expense: — · Firm income: $80,000
Matched citations: H.R.9599
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: S.1862
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: S.2903
Clinical Trial Modernization Act
2026 · third_quarter · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: S.4440
340B Program. Home Infusion for Part B Products. S.864: HELP Copays Act. Medicare Reimbursement for New Technologies.
Client expense: — · Firm income: $80,000
Matched citations: S.864
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Education about 340b program.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
Tax proposals building on One Big Beautiful Bill Act law and implementation (R&D expensing, BEAT, FDII, Corporate Alternative Minimum Tax) HR 591 - Defending American Jobs and Investment Act HR 1414 - Camerons Law, to restore orphan drug research tax credit HR 1911 - To amend the Internal Revenue Code of 1986 to provide that certain payments to foreign related parties subject to sufficient foreign tax are not treated as base erosion payments HR 1990 - American Innovation and R&D Competitiveness Act of 2025 S.1605 - International Competition for American Jobs Act S.1639 - American Innovation and Jobs Act S.3841 - Last Sale Valuation Act of 2026 Issues related to a Most Favored Nations policy in Medicare and Medicaid Issues related to the renewable energy tax credits and other energy credits included in the Inflation Reduction Act Most Favored Nations and pharmaceutical R&D innovation Most Favored Nation drug pricing proposals Pharmaceutical investment and pricing issues in ex-US countries US trade tools (investigations, tariffs, trade agreements, congressional oversight, rules of origin, CBP enforcement, investment screening) US-Mexico-Canada trade agreement (USMCA)
Client expense: $1,680,000 · Firm income: —
Matched citations: HR 1414
Tax proposals building on One Big Beautiful Bill Act law and implementation (R&D expensing, BEAT, FDII, Corporate Alternative Minimum Tax) Tariffs/trade policies related to tariffs on pharmaceuticals Issues related to the renewable energy tax credits and other energy credits included in the Inflation Reduction Act HR 591 - Defending American Jobs and Investment Act HR 1414 - Camerons Law, to restore orphan drug research tax credit HR 1990 - American Innovation and R&D Competitiveness Act of 2025 HR 1911 - To amend the Internal Revenue Code of 1986 to provide that certain payments to foreign related parties subject to sufficient foreign tax are not treated as base erosion payments S 1605 - International Competition for American Jobs Act S 1639 - American Innovation and Jobs Act
Client expense: $1,680,000 · Firm income: —
Matched citations: HR 1414
Source: Senate LDA